![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » THERAVANCE INITIATES PHASE I STUDY WITH INVESTIGATIONAL MEDICINE FOR GASTROINTESTINAL MOTILITY DYSFUNCTION
THERAVANCE INITIATES PHASE I STUDY WITH INVESTIGATIONAL MEDICINE FOR GASTROINTESTINAL MOTILITY DYSFUNCTION
Theravance has enrolled the first subjects in a Phase I clinical study designed to assess the safety, tolerability and pharmacokinetics of its investigational gastrointestinal (GI) prokinetic, TD-2749.
TD-2749 is a selective 5-HT4 agonist discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, opioid-induced constipation, functional dyspepsia and diabetic gastroparesis.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct